A review of malaria vaccine clinical projects based on the WHO rainbow table

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Schwartz, Lauren ^a,b   Brown, Graham V ^c   Genton, Blaise ^d,e   Moorthy, Vasee S ^a,f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

ARTICLE; DRUG RESEARCH; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALARIA CONTROL; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; FACTUAL DATABASE; HUMAN; IMMUNOLOGY; INTERNET; MALARIA; MEDICAL RESEARCH; REVIEW;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG DISCOVERY; HUMANS; INTERNET; MALARIA; MALARIA VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84855494087     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-11     Document Type: Article

References (180)

1. Malaria Vaccine Rainbow Tables. WHO, http://www.who.int/vaccine-research/ links/Rainbow/en/index.html
2. Changes in the burden of malaria in sub-Saharan Africa. O'Meara WP, Mangeni JN, Steketee R, Greenwood B, Lancet Infect Dis 2010 10 545 555
3. World Malaria Report 2010. http://www.who.int/malaria
4. Gamma globulin and acquired immunity to malaria. Cohen S, McGregor IA, Carrington S, Nature 1961 192 733 737
5. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P, J Exp Med 1990 172 1633 1641
6. Immunization against sporozoites. Cochrane AH, Nussenzweig RS, Nardin EH, Malaria New York Academic Press, Kreier JP, 1980 3
7. Immunization of man against sporozite-induced falciparum malaria. Clyde DF, Most H, McCarthy VC, Vanderberg JP, Am J Med Sci 1973 266 169 177
8. Malaria Vaccine Technology Roadmap Final Report. http://www. malariavaccine.org/files/Malaria-Vaccine-TRM-Final-000.pdf
9. Moran M, Guzman J, Ropars A, Jorgensen M, McDonald A, Potter S, Haile-Selassie H, The malaria product pipeline: planning for the future London, UK: The George Institute for International Health 2007
10. Reducing empiricism in malaria vaccine design. Moorthy VS, Kieny MP, Lancet Infect Dis 2010 10 204 211
11. A research agenda for malaria eradication: vaccines. malERA Consultative Group on Vaccines, PLoS Med 2011 8 1000398
12. Measures of efficacy of anti-malarial interventions against malaria transmission. MALVAC, 2010 http://www.who.int/vaccine-research/malaria- malvac2010/en/index.html
13. A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. Kubler-Kielb J, Majadly F, Biesova Z, Mocca CP, Guo C, Nussenzweig R, Nussenzweig V, Mishra S, Wu Y, Miller LH, Keith JM, Liu TY, Robbins JB, Schneerson R, Proc Natl Acad Sci USA 2010 107 1172 1177
14. Study of VMP001 and AS01B in Healthy Malaria-Naive Adults. http://clinicaltrials.gov/ct2/show/NCT01157897
15. Immunity to malaria: more questions than answers. Langhorne J, Ndungu FM, Sponaas AM, Marsh K, Nat Immunol 2008 9 725 732 (Pubitemid 351859155)
16. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA, Corradin G, Persson C, Tewari R, Sinnis P, J Exp Med 2011 208 341 356
17. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Zavala F, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, Nussenzweig RS, Nussenzweig V, Science 1985 228 1436 1440 (Pubitemid 15041321)
18. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, Kazura JW, J Infect Dis 2008 197 519 526 (Pubitemid 351321528)
19. Antisporozoite vaccine for malaria: experimental basis and current status. Nussenzweig RS, Nussenzweig V, Rev Infect Dis 1989 11 Suppl 3 579 585
20. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A, Hum Vaccin 2009 6 90 96
21. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Ballou WR, Parasite Immunol 2009 31 492 500
22. The RTS,S malaria vaccine. Casares S, Brumeanu TD, Richie TL, Vaccine 2010 28 4880 4894
23. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T, Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K, Riley EM, von Seidlein L, Bejon P, Lancet Infect Dis 2011 11 102 109
24. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01(E) and protection against P. falciparum clinical malaria. Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, Janssens M, Kai O, Jongert E, Lievens M, Leach A, Villafana T, Savarese B, Marsh K, Cohen J, Bejon P, PLoS One 2011 6 25786
25. First results of 3 trial of RTS,S/AS01 malaria vaccine in African children. The RTS, S Clinical Trials Partnership, N Engl J Med 2011 365 1863 1875
26. A vaccine for malaria. White NJ, N Engl J Med 2011 365 1926 1927
27. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F, Proc Natl Acad Sci USA 1993 90 5214 5218 (Pubitemid 23183008)
28. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitie MA, Dubois MC, Komisar J, Cobb M, Kester KE, Dubois P, Cohen J, Goudsmit J, Heppner DG, Stewart VA, Vaccine 2008 26 2818 2823
29. Adenovirus Vaccine for Malaria. http://clinicaltrials.gov/ct2/show/ NCT00371189
30. Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso. http://clinicaltrials.gov/ct2/show/NCT01018459
31. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJ, Goudsmit J, Barouch DH, J Clin Microbiol 2006 44 3781 3783 (Pubitemid 46768807)
32. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN, Lancet 2008 372 1881 1893
33. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, G HD Jr, Infect Immun 2007 75 2283 2290 (Pubitemid 46744316)
34. Safety, immunogenicity and efficacy against of a combined malaria vaccine in healthy malaria-nave adults. http://clinicaltrials.gov/ct2/show/NCT01366534
35. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. Schofield L, Ferreira A, Altszuler R, Nussenzweig V, Nussenzweig RS, J Immunol 1987 139 2020 2025 (Pubitemid 17141640)
36. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, Colloca S, Cortese R, Hill AV, Infect Immun 2010 78 145 153
37. Expression of thrombospondin-related anonymous protein in Plasmodium falciparum sporozoites [letter]. Cowan G, Krishna S, Crisanti A, Robson K, Lancet 1992 339 1412 1413
38. Characterization of Plasmodium falciparum sporozoite surface protein 2. Rogers WO, Malik A, Mellouk S, Nakamura K, Rogers MD, Szarfman A, Gordon DM, Nussler AK, Aikawa M, Hoffman SL, Proc Natl Acad Sci USA 1992 89 9176 9180
39. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, Nicosia A, Colloca S, Cortese R, Folgori A, Hill AV, Vaccine 29 256 265
40. A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP. http://clinicaltrials.gov/ct2/show/NCT00890019
41. A study to assess the effectiveness of a new malaria vaccine candidate by infecting vaccinated volunteers with malaria parasites. http://clinicaltrials. gov/ct2/show/NCT00890760
42. EP1300 Polyepitope DNA vaccine against Plasmodium falciparum malaria. http://clinicaltrials.gov/ct2/show/NCT01169077
43. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S, Vaccine 2008 26 2100 2110
44. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB, J Virol 2009 83 4624 4630
45. Electroporation delivery of DNA vaccines: prospects for success. Sardesai NY, Weiner DB, Curr Opin Immunol 2011 23 421 429
46. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DD, PLoS One 2011 6 19252
47. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, J Infect Dis 2002 185 1155 1164 (Pubitemid 34297774)
48. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BK, Hum Vaccin 2010 6 97 106
49. MALVAC 2009: Progress and challenges with development of whole organism malaria vaccines for endemic countries. Pinder M, Moorthy VS, Akanmori BD, Genton B, Brown GV, Vaccine 2009 28 4695 4702
50. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, et al. Science 2011 334 475 480
51. Experimental PfSPZ Vaccine in Adults Without Malaria. http://clinicaltrials.gov/ct2/show/NCT01441167
52. Negative selection using yeast cytosine deaminase/uracil phosphoribosyl transferase in Plasmodium falciparum for targeted gene deletion by double crossover recombination. Maier AG, Braks JA, Waters AP, Cowman AF, Mol Biochem Parasitol 2006 150 118 121 (Pubitemid 44332581)
53. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. VanBuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, Dowler MG, Sacci JB, Kangwanrangsan N, Tsuboi T, Kneteman NM, Heppner DG, Murdock BA, Mikolajczak SA, Aly AS, Cowman AF, Kappe SH, Proc Natl Acad Sci USA 2009 106 13004 13009
54. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, Berthoud T, Andrews L, Andersen RF, Moore A, Gilbert SC, Poulton I, Dubovsky F, Tierney E, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Hill AV, Infect Immun 2006 74 2706 2716 (Pubitemid 43672979)
55. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Imoukhuede EB, Berthoud T, Milligan P, Bojang K, Ismaili J, Keating S, Nwakanma D, Keita S, Njie F, Sowe M, Todryk S, Laidlaw SM, Skinner MA, Lang T, Gilbert S, Greenwood BM, Hill AV, Vaccine 2006 24 6526 6533 (Pubitemid 44511860)
56. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8(+) responses in mice. Miyahira Y, Garcia-Sastre A, Rodriguez D, Rodriguez JR, Murata K, Tsuji M, Palese P, Esteban M, Zavala F, Nussenzweig RS, Proc Natl Acad Sci USA 1998 95 3954 3959 (Pubitemid 28173235)
57. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV, Infect Immun 2006 74 5933 5942 (Pubitemid 44484581)
58. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, Berthoud T, Andrews L, Bejon P, Poulton I, Butcher G, Watkins K, Sinden RE, Leach A, Moris P, Tornieporth N, Schneider J, Dubovsky F, Tierney E, Williams J, G HD, Gilbert SC, Cohen J, Hill AV, Vaccine 2006 24 2850 2859
59. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, de Taisne C, Norman JA, Hoffman SL, Science 1998 282 476 480 (Pubitemid 28483675)
60. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, Carucci DJ, Hedstrom RC, Rahardjo N, Gay T, Hobart P, Stout R, Jones TR, Richie TL, Parker SE, Doolan DL, Norman J, Hoffman SL, Proc Natl Acad Sci USA 2001 98 10817 10822 (Pubitemid 32878703)
61. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL, Vaccine 2000 18 1893 1901 (Pubitemid 30122852)
62. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, Charoenvit Y, Epstein JE, Luke T, Freilich DA, Norman J, Hoffman SL, Infect Immun 2005 73 2863 2872 (Pubitemid 40570355)
63. Induction in Humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T, Banania JG, Chattopadhyay R, de la Vega P, Richie TL, Tornieporth N, Doolan DL, Kester KE, Heppner DG, Norman J, Carucci DJ, Cohen JD, Hoffman SL, J Immunol 2004 172 5561 5569 (Pubitemid 38542058)
64. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Epstein JE, Charoenvit Y, Kester KE, Wang R, Newcomer R, Fitzpatrick S, Richie TL, Tornieporth N, Heppner DG, Ockenhouse C, Majam V, Holland C, Abot E, Ganeshan H, Berzins M, Jones T, Freydberg CN, Ng J, Norman J, Carucci DJ, Cohen J, Hoffman SL, Vaccine 2004 22 1592 1603 (Pubitemid 38447205)
65. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Nardin EH, Oliveira GA, Calvo-Calle JM, Wetzel K, Maier C, Birkett AJ, Sarpotdar P, Corado ML, Thornton GB, Schmidt A, Infect Immun 2004 72 6519 6527 (Pubitemid 39425433)
66. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. Gregson AL, Oliveira G, Othoro C, Calvo-Calle JM, Thorton GB, Nardin E, Edelman R, PloS One 2008 3 1556
67. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, Dubovsky F, Tierney E, Gleiter CH, Boehmer G, Luty AJ, Ramharter M, Thornton GB, Kremsner PG, Nardin EH, Infect Immun 2005 73 3587 3597 (Pubitemid 40745903)
68. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, Maier C, Andrews L, Andersen RF, Gilbert S, Poulton I, Webster D, Dubovsky F, Tierney E, Sarpotdar P, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Thornton GB, Hill AV, Vaccine 2005 23 857 864 (Pubitemid 39643172)
69. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Lopez JA, Weilenman C, Audran R, Roggero MA, Bonelo A, Tiercy JM, Spertini F, Corradin G, Eur J Immunol 2001 31 1989 1998 (Pubitemid 32640714)
70. The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial. Audran R, Lurati-Ruiz F, Genton B, Blythman HE, Ofori-Anyinam O, Reymond C, Corradin G, Spertini F, PloS One 2009 4 7304
71. Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Genton B, D'Acremont V, Lurati-Ruiz F, Verhage D, Audran R, Hermsen C, Wolters L, Reymond C, Spertini F, Sauerwein R, Vaccine 2010 28 6573 6580
72. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in gambian men. Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, Gilbert SC, Walraven G, Hill AV, J Infect Dis 2004 189 2213 2219 (Pubitemid 38757193)
73. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, Hill AV, J Immunol 2005 174 449 455 (Pubitemid 40007434)
74. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV, Proc Natl Acad Sci USA 2005 102 4836 4841 (Pubitemid 40471540)
75. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, Lang T, Gilbert SC, Peshu N, Marsh K, Hill AV, Vaccine 2006 24 4709 4715 (Pubitemid 43776788)
76. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Bejon P, Peshu N, Gilbert SC, Lowe BS, Molyneux CS, Forsdyke J, Lang T, Hill AV, Marsh K, Clin Infect Dis 2006 42 1102 1110
77. Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. Bejon P, Kai OK, Mwacharo J, Keating S, Lang T, Gilbert SC, Peshu N, Marsh K, Hill AV, Eur J Immunol 2006 36 2264 2272 (Pubitemid 44251770)
78. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S, Keating S, Lang T, Lowe B, Gikonyo C, Molyneux C, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AV, PLoS Clin Trials 2006 1 29
79. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AV, PloS One 2007 2 707
80. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV, Nat Med 2003 9 729 735 (Pubitemid 36749222)
81. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, Hill AS, PLoS Med 2004 1 33
82. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. Moorthy VS, Pinder M, Reece WH, Watkins K, Atabani S, Hannan C, Bojang K, McAdam KP, Schneider J, Gilbert S, Hill AV, J Infect Dis 2003 188 1239 1244 (Pubitemid 37338989)
83. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, Robson KJ, Hill AV, Proc Natl Acad Sci USA 2004 101 290 295 (Pubitemid 38084243)
84. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, Poulton I, Prieur E, Correa S, Rowland R, Lang T, Williams J, Gilbert SC, Sinden RE, Todryk S, Hill AV, Vaccine 2011 29 7514 7522
85. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE, Trends Parasitol 2001 17 219 223 (Pubitemid 32422165)
86. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr, Vaccine 2010 28 5135 5144
87. Safety and efficacy study of Plasmodium falciparum LSA-3 malaria vaccine. http://clinicaltrials.gov/ct2/show/NCT00509158
88. Cardiac complication after experimental human malaria infection: a case report. Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G, Stalenhoef A, Druilhe P, Sauerwein R, van der Ven A, Malar J 2009 8 277
89. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, Hill AV, Imoukhuede EB, Kumar S, Loucq C, Marsh K, Ockenhouse CF, Richie TL, Sauerwein RW, Vaccine 2009 27 5719 5725
90. A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Collins WE, Jeffery GM, Am J Trop Med Hyg 1999 61 20 35
91. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Holder AA, Parasitology 2009 136 1445 1456
92. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. Fowkes FJ, Richards JS, Simpson JA, Beeson JG, PLoS Med 2010 7 1000218
93. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks MD, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ, Mol Ther 2011 19 2269 2276
94. A study of the safety and effectiveness of two new malaria Vaccines. http://clinicaltrials.gov/ct2/show/NCT01003314
95. Study to assess efficacy of new malaria vaccine candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. http://clinicaltrials.gov/ct2/show/NCT01142765
96. A study to determine the effects of an investigational malaria vaccine given to adults living in the United States. http://clinicaltrials.gov/ct2/show/ NCT00666380
97. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR, PLoS One 2009 4 4708
98. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S, Audran R, Bouzidi A, Oeuvray C, Roussilhon C, PLoS Med 2005 2 344
99. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F, Infect Immun 2005 73 8017 8026 (Pubitemid 41740288)
100. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O, Vaccine 2007 25 2723 2732 (Pubitemid 46400921)
101. Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Nebie I, Diarra A, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Soulama I, Cousens S, Leroy O, Sirima SB, Parasite Immunol 2009 31 474 480
102. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P, Malar J 2009 8 163
103. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. Sirima SB, Tiono AB, Ouedraogo A, Diarra A, Ouedraogo AL, Yaro JB, Ouedraogo E, Gansane A, Bougouma EC, Konate AT, Kabore Y, Traore A, Chilengi R, Soulama I, Luty AJ, Druilhe P, Cousens S, Nebie I, PloS One 2009 4 7549
104. Immunogenicity, efficacy and safety study of an MSP3-LSP (Long Synthetic Peptide) malaria vaccine. http://clinicaltrials.gov/ct2/show/NCT00652275
105. Protection against malaria by MSP3 candidate vaccine. Sirima SB, Cousens S, Druilhe P, N Engl J Med 2011 365 1062 1064
106. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, Gaye O, Roeffen W, Remarque EJ, Sauerwein R, Garcia A, Luty AJ, PloS One 2009 4 7590
107. Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. Udhayakumar V, Kariuki S, Kolczack M, Girma M, Roberts JM, Oloo AJ, Nahlen BL, Lal AA, Am J Trop Med Hyg 2001 65 100 107 (Pubitemid 32744213)
108. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Takala SL, Plowe CV, Parasite Immunol 2009 31 560 573
109. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr, Vaccine 2007 25 4203 4212 (Pubitemid 46635946)
110. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusu A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala SL, Lyke KE, Plowe CV, PloS One 2008 3 1465
111. Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. Lyke KE, Daou M, Diarra I, Kone A, Kouriba B, Thera MA, Dutta S, Lanar DE, Heppner DG, Doumbo OK, Plowe CV, Sztein MB, Vaccine 2009 27 2171 2176
112. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV, PLoS One 2009 5 9041
113. A field trial to assess a blood-stage malaria vaccine. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV, N Engl J Med 2011 365 1004 1013
114. Phase 1/2a study of the malaria vaccine candidate Apical Membrane Antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois M-C, Ballou WR, Cohen J, Heppner DG Jr, PLoS One 2009 4 5254
115. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, Fay MP, Saul A, Zhu D, Rausch K, Moretz S, Zhou H, Long CA, Miller LH, Treanor J, PloS One 2008 3 2940
116. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, Sissoko MS, Fay MP, Guindo MA, Kante O, Saye R, Miura K, Long C, Mullen GE, Pierce M, Martin LB, Rausch K, Dolo A, Diallo DA, Miller LH, Doumbo OK, Vaccine 2009 27 7292 7298
117. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, Sissoko MS, Kone M, Diallo AI, Saye R, Guindo MA, Kante O, Niambele MB, Miura K, Mullen GE, Pierce M, Martin LB, Dolo A, Diallo DA, Doumbo OK, Miller LH, Saul A, Vaccine 2009 27 3090 3098
118. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, Dicko A, Niangaly A, Duan J, Ellis RD, Miller LH, Su XZ, Plowe CV, Doumbo OK, Malar J 2010 9 175
119. A Study of AdCh63 AMA1 Alone and With MVA AMA1. http://clinicaltrials. gov/ct2/show/NCT01095055
120. Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly. http://clinicaltrials.gov/ct2/show/NCT00347555
121. The safety and immunogenicity of recombinant EBA 175-RII NG malaria vaccine in healthy adults living in a non-endemic area. El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, Lee Sim BK, Long C, Keitel WA, Clin Vaccine Immunol 17 1552 1559
122. EBA-175 RII-NG malaria vaccine administered intramuscularly in semi-immune adults. http://clinicaltrials.gov/ct2/show/NCT01026246
123. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N, Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, Takahashi M, Parasitol Intl 2010 59 380 386
124. ISRCTN71619711-BK-SE36 two-stage phase 1b vaccine trial for falciparum malaria. http://www.controlled-trials.com/ISRCTN71619711
125. Phase I study of the safety and immunogenicity of BSAM-2/ Alhydrogel(Registered Trademark) + CPG 7909, an asexual blood stage vaccine for Plasmodium falciparum malaria in adults in the US and Mali. http:// clinicaltrials.gov/ct2/show/NCT00889616
126. A first-in-man clinical trial to evaluate the safety and immunogenicity of different doses of a malaria Vaccine (JAIVAC-1) in healthy Indian male subjects between 18 to 45 years of age. http://www.ctri.nic.in/Clinicaltrials/ pmaindet2.php?trialid=1507
127. Erythrocyte invasion and functionally inhibitory antibodies in Plasmodium falciparum malaria. Persson KE, Acta Trop 114 138 143
128. Safety and immunogenicity of GMZ2-a MSP3-GLURP fusion protein malaria vaccine candidate. Esen M, Kremsner PG, Schleucher R, Gassler M, Imoukhuede EB, Imbault N, Leroy O, Jepsen S, Knudsen BW, Schumm M, Knobloch J, Theisen M, Mordmuller B, Vaccine 2009 27 6862 6868
129. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Mordmuller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, Murbeth RE, Chilengi R, Noor R, Kilama WL, Imoukhuede EB, Imbault N, Leroy O, Theisen M, Jepsen S, Milligan P, Fendel R, Kremsner PG, Issifou S, Vaccine 2010 28 6698 6703
130. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. Belard S, Issifou S, Hounkpatin AB, Schaumburg F, Ngoa UA, Esen M, Fendel R, de Salazar PM, Murbeth RE, Milligan P, Imbault N, Imoukhuede EB, Theisen M, Jepsen S, Noor RA, Okech B, Kremsner PG, Mordmuller B, PLoS One 2011 6 22525
131. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Sturchler D, Vaccine 1999 17 3145 3159 (Pubitemid 29366996)
132. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N, Rzepczyk C, Smillie A, Anderson K, Pombo D, Allworth A, Eisen D, Anders R, Saul A, Vaccine 2000 18 1925 1931 (Pubitemid 30122856)
133. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, Irving DO, Briggs WR, Mai A, Ginny M, Adiguma T, Rare L, Giddy A, Reber-Liske R, Stuerchler D, Alpers MP, Vaccine 2000 18 2504 2511 (Pubitemid 30207035)
134. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP, Vaccine 2003 22 30 41 (Pubitemid 37357150)
135. The malaria vaccine development program in Papua New Guinea. Genton B, Anders RF, Alpers MP, Reeder JC, Trends Parasitol 2003 19 264 270 (Pubitemid 36638728)
136. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP, J Infect Dis 2002 185 820 827 (Pubitemid 34226210)
137. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG, Group MSPW, Vaccine 2006 24 3009 3017
138. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV, Mali FMPWG, PLoS Clin Trials 2006 1 34
139. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG Jr, Vaccine 2007 25 176 184 (Pubitemid 44855235)
140. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, Apollo OJ, Allen OG, Tucker K, Soisson LA, Diggs C, Leach A, Wittes J, Dubovsky F, Stewart VA, Remich SA, Cohen J, Ballou WR, Holland CA, Lyon JA, Angov E, Stoute JA, Martin SK, Heppner DG, Group MSPMVW, PLoS Clin Trials 2006 1 32
141. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. Malkin E, Long CA, Stowers AW, Zou L, Singh S, MacDonald NJ, Narum DL, Miles AP, Orcutt AC, Muratova O, Moretz SE, Zhou H, Diouf A, Fay M, Tierney E, Leese P, Mahanty S, Miller LH, Saul A, Martin LB, PLoS Clin Trials 2007 2 12
142. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, Narum DL, Zhu D, Mullen GE, Mahanty S, Miller LH, Durbin AP, PloS One 2010 5 8787
143. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. Crompton PD, Mircetic M, Weiss G, Baughman A, Huang CY, Topham DJ, Treanor JJ, Sanz I, Lee FE, Durbin AP, Miura K, Narum DL, Ellis RD, Malkin E, Mullen GE, Miller LH, Martin LB, Pierce SK, J Immunol 2009 182 3318 3326
144. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, Martin LB, Pierce MA, Ellis RD, Mullen GE, Long CA, Clin Vaccine Immunol 2009 16 963 968
145. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Pierce MA, Ellis RD, Martin LB, Malkin E, Tierney E, Miura K, Fay MP, Marjason J, Elliott SL, Mullen GE, Rausch K, Zhu D, Long CA, Miller LH, Vaccine 2010 28 2236 2242
146. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, Imoukhuede E, Jepsen S, Ofori-Anyinam O, Faber B, Kocken CH, Arnold M, Walraven V, Teelen K, Roeffen W, de Mast Q, Ballou WR, Cohen J, Dubois MC, Ascarateil S, van der Ven A, Thomas A, Sauerwein R, PloS One 2008 3 3960
147. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, Rzepczyk C, Martin LB, Taylor D, Eisen DP, Irving DO, Pye D, Crewther PE, Hodder AN, Murphy VJ, Anders RF, Vaccine 2005 23 3076 3083 (Pubitemid 40462448)
148. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. Hu J, Chen Z, Gu J, Wan M, Shen Q, Kieny MP, He J, Li Z, Zhang Q, Reed ZH, Zhu Y, Li W, Cao Y, Qu L, Cao Z, Wang Q, Liu H, Pan X, Huang X, Zhang D, Xue X, Pan W, PLoS One 2008 3 1952
149. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, Dubovsky F, Liu J, Wang Q, Pan X, Chen T, Giersing B, Xu Y, Kang X, Gu J, Shen Q, Tucker K, Tierney E, Pan W, Long C, Cao Z, Vaccine 2008 26 6864 6873
150. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, Bolad A, Berzins K, Corradin G, Leroy O, Theisen M, Sauerwein RW, Vaccine 2007 25 2930 2940 (Pubitemid 46412561)
151. Clinical trial for malaria vaccines to test for safety, immune response and protection against malaria. http://clinicaltrials.gov/ct2/show/NCT00870987
152. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: Safety and immunogenicity in seronegative adults. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Manohar N, Richie NO, Wood C, Long CA, Regis D, Williams FT, Shi M, Chuang I, Spring M, Epstein JE, Mendoza-Silveiras J, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Soisson L, Diggs C, Carucci D, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL, PLoS One 2011 6 24586
153. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: Safety, immunogenicity and protective efficacy of the CSP component. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S, Maiolatesi S, Reyes S, Steinbeiss V, Fedders C, Smith K, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Murphy J, Komisar J, Williams J, Shi M, Brambilla D, Manohar N, Richie NO, Wood C, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Diggs C, Soisson L, Carucci D, Levine G, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL, PLoS One 2011 6 25868
154. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, Zurbriggen R, PloS One 2007 2 1018
155. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. Okitsu SL, Silvie O, Westerfeld N, Curcic M, Kammer AR, Mueller MS, Sauerwein RW, Robinson JA, Genton B, Mazier D, Zurbriggen R, Pluschke G, PLoS One 2007 2 1278
156. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, Dunachie S, Andrews L, Williams JL, Sinden R, Gilbert SC, Pluschke G, Zurbriggen R, Hill AV, PLoS One 2008 3 1493
157. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized Phase 1b trial in semi-immune adults & children. Cech PG, Aebi T, Abdallah MS, Mpina M, Machunda EB, Westerfeld N, Stoffel SA, Zurbriggen R, Pluschke G, Tanner M, Daubenberger C, Genton B, Abdulla S, PLoS One 2011 6 22273
158. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Kashala O, Amador R, Valero MV, Moreno A, Barbosa A, Nickel B, Daubenberger CA, Guzman F, Pluschke G, Patarroyo ME, Vaccine 2002 20 2263 2277 (Pubitemid 34497037)
159. Vaccines for preventing malaria (SPf66). Graves P, Gelband H, Cochrane Database Syst Rev 2006 D005966
160. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M, Lancet 1993 341 705 710 (Pubitemid 23085175)
161. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, Thomas MC, Lopez MC, Armstrong Schellenberg JRM, Hayes R, Smith T, Weiss N, Tanner M, Lancet 1994 344 1175 1181 (Pubitemid 24323705)
162. A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design. Alonso PL, Tanner M, Smith T, Hayes RJ, Schellenberg JA, Lopez MC, Bastos de Azevedo I, Menendez C, Lyimo E, Weiss N, Vaccine 1994 12 181 186 (Pubitemid 24041938)
163. Efficacy trial of malaria vaccine SPf66 in Gambian infants. D'Alessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, Jawara M, Langerock P, George MO, Targett GA, Lancet 1995 346 462 467
164. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Teuscher T, Schellenberg JR, Bastos de Azevedo I, Hurt N, Smith T, Hayes R, Masanja H, Silva Y, Lopez MC, Kitua A, Vaccine 1994 12 328 336 (Pubitemid 24071955)
165. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon DM, White NJ, Sadoff JC, Heppner DG, Lancet 1996 348 701 707 (Pubitemid 26302304)
166. Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66. Bojang KA, Obaro SK, Leach A, D'Alessandro U, Bennett S, Metzger W, Ballou WR, Targett GA, Greenwood BM, Parasite Immunol 1997 19 579 581 (Pubitemid 28022536)
167. An efficacy trial of the malaria vaccine SPf66 in Gambian infants - second year of follow-up. Bojang KA, Obaro SK, D'Alessandro U, Bennett S, Langerock P, Targett GA, Greenwood BM, Vaccine 1998 16 62 67 (Pubitemid 27504805)
168. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Acosta CJ, Galindo CM, Schellenberg D, Aponte JJ, Kahigwa E, Urassa H, Schellenberg JR, Masanja H, Hayes R, Kitua AY, Lwilla F, Mshinda H, Menendez C, Tanner M, Alonso PL, Trop Med Int Health 1999 4 368 376 (Pubitemid 29283081)
169. Serological responses of Gambian children to immunization with the malaria vaccine SPf66. Metzger WG, Haywood M, D'Alessandro U, Drakeley CJ, Weiss H, Bojang K, Targett GA, Greenwood BM, Parasite Immunol 1999 21 335 340 (Pubitemid 29296737)
170. Update on the clinical development of candidate malaria vaccines. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, Kester KE, Lanar DE, Lyon J, Hill AV, Pan W, Cohen JD, Am J Trop Med Hyg 2004 71 239 247 (Pubitemid 39121328)
171. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A, Vaccine 2005 23 3131 3138
172. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP, PLoS One 2008 3 2636
173. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A, Malar J 2007 6 107
174. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Qian F, Rausch KM, Muratova O, Zhou H, Song G, Diouf A, Lambert L, Narum DL, Wu Y, Saul A, Miller LH, Long CA, Mullen GE, Vaccine 2008 26 2521 2527
175. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Qian F, Wu Y, Muratova O, Zhou H, Dobrescu G, Duggan P, Lynn L, Song G, Zhang Y, Reiter K, MacDonald N, Narum DL, Long CA, Miller LH, Saul A, Mullen GE, Vaccine 2007 25 3923 3933 (Pubitemid 46616999)
176. Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel. http://www.clinicaltrials.gov/ct2/show/NCT01434381
177. Why is Plasmodium vivax a neglected tropical disease? Carlton JM, Sina BJ, Adams JH, PLoS Negl Trop Dis 2011 5 1160
178. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Moorthy V, Reed Z, Smith PG, Vaccine 2007 25 5115 5123 (Pubitemid 46915464)
179. MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials - scientific, regulatory and public health perspectives. Moorthy VS, Reed Z, Smith PG, Vaccine 2009 27 624 628
180. Development of vaccines to prevent malaria in pregnant women: WHO MALVAC meeting report. Menendez C, Moorthy VS, Reed Z, Bardaji A, Alonso P, Brown GV, Expert Rev Vaccines 2011 10 1271 1280